Recent evidence has shown that the EBV oncogene LMP1 is not expressed at high levels 14 early after EBV-infection of primary B cells, despite its being essential for the long-term outgrowth 15 of immortalized lymphoblastoid cell lines (LCLs). In this study, we found that expression of LMP1 16 increased fifty-fold between seven days post infection and the LCL state. Metabolic labeling of 17 nascently transcribed mRNA indicated this was primarily a transcription-mediated event. EBNA2, 18 the key viral transcription factor regulating LMP1, and CTCF, an important chromatin insulator, 19
EBV is a highly successful pathogen that latently infects greater than 90% of adults 28 worldwide and is also causally associated with a number of B-cell malignancies. EBV expresses 29 a set of viral oncoproteins and non-coding RNAs during the latent life cycle with the potential to 30 promote cancer. Critical among these is the viral latent membrane protein, LMP1. Prior work 31 suggests that LMP1 is essential for EBV to immortalize B cells, but our recent work indicates that 32 Diffuse Large B Cell Lymphoma (DLBCL) (1). Characteristic of Latency III is expression of the 43 essential viral oncogene latent membrane protein 1 (LMP1), which is a constitutively active TNF 44 receptor homologue that induces the host NFB and AP-1 signaling pathways to promote survival 45 (2) (3) (4) (5) . LMP1 is both necessary for EBV immortalization of primary human B cells and sufficient to 46 induce lymphomas when expressed in the murine B cell compartment (6, 7). The regions of the 47 LMP1 cytoplasmic tail that engage TNFR associated factors (TRAFs) and TNFR associated death 48 domain (TRADD) responsible for NFB activation are coincident with the regions required for 49 9) . LCLs are functionally addicted to the NFB signaling 50 induced by LMP1 as inhibition of this pathway results in apoptosis (3). 51
Studies of LMP1 transcriptional regulation have defined cis-acting elements and trans-52 acting factors important in controlling its expression. In epithelial cells, LMP1 expression is driven 53 by a unique promoter found within the viral terminal repeats (10, 11). However, transcription of 54 LMP1 in Latency III expressing B cells is initiated at a bi-directional LMP1/LMP2B promoter (12) . 55
The critical activator of this Latency III promoter is Epstein-Barr Nuclear Antigen 2 (EBNA2), which 56 binds to a so-called EBNA2-response element (E2RE) through the host factors RBP-J and PU.1 57 EBNA2 activity is not broadly suppressed during early infection (32). However, it remained a 120 possibility that LMP1 expression was low during early infection because of poor EBNA2 121 recruitment to the bi-directional LMP1/2B promoter. To address this, we performed Chromatin 122
Immuno-precipitation (ChIP) for EBNA2 at day 7 post infection and in LCLs. LMP1 and LMP2 are 123 transcribed from a complex and overlapping region of the EBV episome near the terminal repeats 124 (TR), diagrammed in Fig. 2A . We found that EBNA2 was recruited comparably to the LMP1 125 promoter and the viral C promoter both early after infection and in LCLs (Fig. 2B) . A region in the 126 gene body of EBNA3C distal to both the LMP1p and the Cp was used as a negative control (Fig.  127   2B) . Similarly, EBNA2 was recruited to the two major c-Myc upstream enhancer loci (31) as well 128 as the CD23 promoter comparably at 7 days post infection as in LCLs (Fig. 2C) . Despite the lack 129 of change in EBNA2 occupancy at early and late times post infection, the activating histone mark 130 H3K9 Acetyl was enriched at the LMP1p in LCLs, correlating with the observed increased level 131 of transcription (Fig. 2D) . A recent publication has implicated the chromatin architecture mediated 132 by CTCF at a single CTCF site downstream of LMP1 (here called the CTCF-Response Element) 133 to be important for H3K9 Acetylation and transcription at the LMP1 promoter (24). We assayed 134 for CTCF-occupancy at both this CTCF-RE as well as the EBV enhancer found in the EBER/OriP 135 region of the genome and found that CTCF occupancy did not change between day 7 post 136 infection cells and LCLs (Fig. 2E) . 137 c-Myc suppresses LMP1 transcription. Despite EBNA2 recruitment to the LMP1 promoter, 138 reduced H3K9 acetylation suggested poor LMP1 transcription. Early after infection when LMP1 139 expression is lowest, c-Myc is strongly activated by EBNA2, and during the time frame that LMP1 140 expression increases the expression of c-Myc and its targets are subsequently attenuated (32). 141
Given this correlation, we sought to test the role of c-Myc in the regulation of LMP1 expression. 142
We first assayed LMP1 transcription using 4sU labeling in EBV-infected Burkitt lymphoma (BL) 143 cell lines that express very high levels of c-Myc relative to LCLs. We found that LMP1 mRNA and 144 . CC-BY 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/168484 doi: bioRxiv preprint first posted online  protein levels were higher in LCLs than in EBV-infected BL41 cells (Fig. 3A-B) . Consistent with 145 our hypothesis, the transcription of LMP1 was significantly lower in EBV-infected BL41 cells 146 relative to LCLs (Fig. 3C) . 147
To directly assess the effect of c-Myc on LMP1 transcription in an LCL, we used the P493-148 6 model of c-Myc and EBNA2 regulation (41, 42) . In this system, EBNA2 (encoded endogenously 149 from the viral genome) is controlled post-translationally by Estrogen (-Estradiol) due to its fusion 150 to a modified estrogen receptor, and heterologous c-Myc expression is provided in trans and 151 controlled transcriptionally through a tetracycline (tet-off) system. We verified that induction of 152 EBNA2 and inactivation of c-Myc (Estrogen+, Tetracycline+) led to an LCL-like phenotype with 153 high levels of LMP1 transcription (Fig. 4A) . However, when removing EBNA2 activity (Estrogen-154 , Tetracycline-) or inducing EBNA2 in the presence of high levels of c-Myc (Estrogen+, 155
Tetracycline-), we observed blunted endogenous LMP1 transcription relative to that induced in 156 the presence of low levels of c-Myc (Fig. 4A) . These changes in transcription correlated with the 157 levels of total LMP1 mRNA and protein ( Fig. 4B-C) , while EBNA2-ER transcription from the 158 endogenous Cp was not affected by c-Myc overexpression (Fig. 4B) The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/168484 doi: bioRxiv preprint first posted online  found that c-Myc mRNA levels decreased and LMP1 mRNA levels increased in a dose-dependent 170 manner ( Fig. 5A-B) . We next treated EBV-infected PBMCs 7 days post infection with BET 171 inhibitors. Consistently, we observed a dose-dependent decrease in c-Myc mRNA and increase 172 in LMP1 mRNA following both JQ1 and OTX015 treatment (Fig. 5C-D) . Therefore, c-Myc activity 173 negatively correlates with LMP1 expression both early and late after infection. 174
DISCUSSION 175
In this study, we determined that transcription of the EBV major latent oncoprotein, LMP1, 176 is suppressed by c-Myc early after primary B cell infection. Transcription of LMP1 increased 177 twenty-five-fold from day 7 to LCL, while the mRNA half-life increased two-fold, leading to an 178 overall fifty-fold increase in LMP1 expression. This change correlated with an approximate two-179 fold increase in the activating histone mark, H3K9Ac, at the LMP1 promoter, but the occupancy 180 The small but significant change in LMP1 half-life could be explained as a post-188 transcriptional effect mediated by miRNAs that are known to target the LMP1 3'UTR. Previous 189 work has shown that the miR17~92 family of c-Myc-induced miRNAs target LMP1 and removal 190 of this miRNA family increased LMP1 protein production (27). Furthermore, our group has shown 191 that miR17~92 are expressed at the highest levels early after infection when LMP1 mRNA and 192 mRNA half-life is lowest (45). This low level "fine-tuning" of LMP1 expression might be critical in 193 . CC-BY 4.0 International license peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/168484 doi: bioRxiv preprint first posted online  the immortalized state when high levels of LMP1 can lead to cytostatic effects on cell growth (28, 194 30). 195 While the LMP1 promoter has been extensively studied in the immortalized LCL, no one 196 has previously characterized promoter occupancy early after infection. We have shown that early 197 after infection EBNA2 is recruited normally to its response element in the LMP1 promoter as well 198 
MATERIALS AND METHODS 233

Cell lines, culture conditions, and viruses 234
Buffy coats were obtained from normal human donors through the Gulf Coast Regional 235
Blood Center (Houston, TX) and peripheral blood mononuclear cells (PBMCs) were isolated by 236
Ficoll Histopaque-1077 gradient (Sigma, H8889). B95-8 strain of Epstein-Barr virus was produced 237 from the B95-8 Z-HT cell line as previously described (52). Virus infections were performed in 238 bulk by adding 50 µL of filtered B95-8 supernatant to 1x10 6 PBMCs. 239
Cell lines were cultured in RPMI 1640 media supplemented with 10-15% heat inactivated 240 fetal bovine serum (Corning), 2 mM L-Glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin 241 (Invitrogen), and 0.5 µg/mL Cyclosporine A (Sigma). P493-6 cells (a kind gift of Dr. Georg 242 Bornkamm, Helmholtz Zentrum München) were cultured with 10% tetracycline-free FBS (Hyclone 243 SH30070), 1 µM -Estradiol, and 1 µg/mL Tetracycline. All cells were cultured at 37°C in a 244 humidified incubator at 5% CO 2. 245
Flow cytometry and sorting 246
To track proliferation, cells were stained with CellTrace Violet (Invitrogen, C34557), a 247 fluorescent proliferation-tracking dye. Cells were first washed in FACS buffer (5% FBS in PBS), 248 stained with the appropriate antibody for 30min-1hr at 4°C in the dark, and then washed again 249 before being analyzed on a BD FACS Canto II. 
Nascent RNA extraction and profiling 256
To assess both mRNA transcription and half-life cells were treated with 4-thiouridine (4sU, 257 Sigma) (200 µM) for exactly one hour. Upon harvesting, total RNA was extracted via TRIzol 258 following the manufacturer's protocol (Life Technologies). 4sU-labelled nascent RNA was then 259 biotinylated using a highly efficient crosslinking reaction using EZ-Link Biotin-HPDP (Pierce) 260 dissolved in DMSO at a concentration of 1 mg/mL or MTSEA Biotin-XX (Biotium Cat# 90066) at 261 20 ng/uL dissolved in DMSO, and labeled RNA was separated from the total population using 262 streptavidin MyOne C1 Dynabeads (Invitrogen) as previously described (39). Subsequently, three 263 populations of RNA were reverse transcribed into cDNA using the High Capacity cDNA kit 264 (Applied Biosystems): total RNA (T), unlabeled RNA (U), and nascent RNA (N). Quantitative real-265 time PCR was then performed on these three populations to discover total RNA abundance, 266 relative transcription rates, and mRNA half-life as previously described (53). In brief, the 267 abundance of mRNA was represented by the measurement of the total RNA sample (T). Relative 
Western blot 301
Cells were pelleted and washed in PBS, and then lysed in 0.1% Triton-containing buffer 302 with Complete protease inhibitors. All protein lysates were run on NuPage 4-12% gradient gels 303 .
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The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/168484 doi: bioRxiv preprint first posted online  (LifeTechnology) and transferred to PVDF membrane (GE Healthcare). Membranes were blocked 304 in 5% milk in TBST and stained with primary antibody overnight at +4°C, followed by a wash and 305 staining with secondary HRP-conjugated antibody for 1 hour at room temperature. Antibodies 306 include LMP1 (S12; gift from Elliot Kieff, Harvard Medical School), c-Myc (Santa Cruz 307
Biotechnology, SC-764), and GAPDH (BioChain Institute, #Y3322). 308
BRD4 Inhibition 309
(+)-JQ1 and OTX015 were purchased from Selleckchem (cat. #S7110 and #S7360, respectively). 310
For LCLs: 311
LCLs were seeded at 3*10^5/mL in the presence of either 0.1% DMSO, 100 or 500 nM JQ1 or 312 100 or 500 nM OTX015 for 24 hours. After 24 hours total mRNA was harvested using the Qiagen 313
RNeasy mini kit (ref #74104) according to manufacturer's instructions. 1 microgram of harvest 314
mRNA was reverse transcribed into cDNA using Applied Biosystems High-Capacity cDNA 315 reverse transcription kit (cat #4368814) according to manufacturer's instructions. RT-qPCR 316 analysis was performed using SYBR Green detection based system (Quanta Bio cat #95072-317 05K) with 5 ng of cDNA used per reaction using an Applied Biosystems StepOne Plus Real Time 318 PCR System. All values were normalized to the endogenous loading control SETDB1. Relative 319 expression values were calculated using the CT method. 320
For PBMCs: 321 Peripheral Blood Mononuclear Cells (PBMCs) were isolated from whole blood, infected with EBV 322 B95-8 and seeded at 1*10^6/mL. Seven days post infection the cells were treated with either 323 0.1% DMSO, 100 or 500 nM JQ1 or 100 or 500 nM OTX015. After 24 hours, total mRNA was 324 harvested as previously described. 1 g of total RNA was reverse transcribed into cDNA as 325 previously described. RT-qPCR analysis was conducted as previously described. 326 Each bar is representative of at least 3 independent donors. Error bars represent SEM. * denotes 348 p<0.05, ** denotes p<0.01 and *** denotes p<0.001 by one-tailed pairwise student's t-test. 349 were isolated from whole blood and infected with EBV. On day 7, they were treated with the 385 were isolated from whole blood and infected with EBV. On day 7, they were treated with the 624 indicated concentrations of JQ1 or OTX015 or 0.1% DMSO for 24 hours before total mRNA was 625 collected for RT-qPCR analysis for c-Myc. (D) Similar experiments as in (C) but RT-qPCR was 626 performed for LMP1. For all panels, each bar represents the average of 3 independent donors. 627
All error bars denote SEM. * denotes p<0.05 and ** denotes p<0.01 by one tailed student's 628 pairwise t-test. 629
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